EU JCA readiness: early signals for development teams
EU Joint Clinical Assessment (JCA) is still early in its implementation. Much of the formal framework is[…]
Why 2026 matters for EU Joint Clinical Assessment readiness
As we move into 2026, EU Joint Clinical Assessments (JCAs) are shifting from policy concept to operational[…]
Europe’s shift to patient evidence: what it means for JCA and rare-disease sponsors
What is changing in Europe’s approach to patient evidence? Recent guidance, including the EMA Reflection Paper on[…]
EU JCA 2025 Explained: What Rare Disease Sponsors Need to Know Now
The EU Joint Clinical Assessment (JCA) is one of the most significant changes to hit market access in years.[…]
JCA is underway…what it really means for rare disease evidence
Introduction This article first appeared in the Rare Focus newsletter on LinkedIn (October 2025). The EU Joint Clinical[…]
Why Patient Voices Are Critical for EU Joint Clinical Assessment (JCA) Now
The European Union is in the midst of a transformative shift toward a harmonized Health Technology Assessment[…]